Primaquine or tafenoquine for preventing malaria in people travelling to or living in endemic areas

  1. To assess the effectiveness of primaquine and tafenoquine for primary prophylaxis against Plasmodium vivax and Plasmodium falciparum infections.
  2. To assess the effectiveness of tafenoquine for terminal prophylaxis of vivax malaria.
  3. To compare the safety profile and compliance rates of tafenoquine and primaquine when used for primary (P. vivax and P. falciparum infections) and terminal (P. vivax infections) prophylaxis.

This is a protocol.